Form Bio

Form Bio is a private, AI-native biotech spinout from Colossal Biosciences, operating as a platform and services company for the genetic medicine sector. Its core technology, FORMsight AI, is applied across vector design, genome integrity analysis, codon optimization, and protein engineering to solve critical bottlenecks in therapeutic development. The company has demonstrated tangible improvements, such as up to 5x better genome integrity and 4.4x yield gains, and is actively engaged in partnered and internal pipeline programs targeting diseases like Duchenne Muscular Dystrophy. Form Bio is pre-revenue and in a pre-clinical stage, focusing on establishing its platform as an essential tool for next-generation drug developers.

FORMsight AI platform for AAV vector & payload design, codon optimization, genome integrity analysis, protein engineering, and CRISPR/gene editing design/analysis.

Form Bio competes with other AI-driven drug discovery platforms (e.g., Recursion, Exscientia, Insilico Medicine) and specialized bioinformatics software providers. Its direct differentiators are its specific focus on genetic medicine challenges (e.g., AAV truncations), its quantifiable yield claims, and its unique heritage in multi-species genome engineering from Colossal.